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Langerhans cells (LCs) have long been considered to
be the major sensitizing cells in the skin by initiating
productive immunity in naive resting T cells. This
picture has changed over the past decade. We now
know (i) that the skin also harbors other types of
dendritic antigen-presenting cells and (ii) that the
genetically driven removal of the LC population
results in increased T-cell immunity against haptens
and infectious agents. It is not clear at present
whether the situation in genetically modified mice is
in any way indicative of the actual in vivo function of
LCs. Exciting and challenging years lie ahead of the
LC research community.
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INTRODUCTION
In 1868, a medical student Paul Langerhans (Figure 1)
reported on the occurrence of a dendritically shaped cell
population within the human epidermis, which now bears
his name (Langerhans, 1868). He had detected them by
impregnating tissue sections with gold chloride, which, at
that time, was a recognized marker for nerves and nervous
tissue. Langerhans was therefore convinced that he had
discovered cutaneous nerves/nerve endings, a view that was
held by several other investigators in the century to come
(Ferreira-Marques, 1951; Niebauer and Sekido, 1965).
Although the advent of electron microscopy in skin research
ultimately disproved the ‘‘nerve’’ theory of Langerhans cells
(LCs), it is noteworthy that now, in 2011, LCs are known to be
surrounded by sensory nerve endings, which, by the secretion
of neuropeptides, can modulate LC immune function (Hosoi
et al., 1993).
A second theory that prevailed for quite some time
claimed that LCs are ontogenetically related to melanocytes.
The reason for this assumption was not only the common
dendritic configuration of LCs and melanocytes, but also the
observation that, in vitiligo, LCs often occupy the space of
destroyed melanocytes (Birbeck et al., 1961). Later, by the
demonstration of LCs in neural crest–deprived, i.e., melano-
cyte-free, mice (Breathnach et al., 1968), it became clear that
the ‘‘melanocyte theory’’ of LC origin was not tenable. The
same was true for the ‘‘keratinocyte’’ theory, which suggested
a common ontogeny between LCs and keratinocytes
(Reams and Tompkins, 1973). At present, however, we fully
appreciate that there is a vivid and, apparently, bidirectional
communication between these two cell systems. Keratino-
cytes elaborate cytokines, growth factors, and hormones that
influence LC phenotype and function (Romani et al., 2010a).
Notably, there also exists a relationship between LC numbers
and the extent of keratinocyte proliferation and differentiation
(Potten and Allen, 1976; Schweizer and Marks, 1977). The
observation of reduced LC numbers in parakeratotic psoriatic
plaques (Ashworth and Mackie, 1986; Placek et al., 1988) is
in keeping with this concept. It will certainly be interesting
and important to determine whether keratinocytes, when
they undergo transformation, lose chemoattracting properties
for LC precursors and, if so, the underlying molecular
mechanisms. Conversely, it remains to be determined why
the induction of squamous metaplasia in the tracheal
epithelium and the urothel, e.g., by a vitamin A–free diet,
coincides with the migration of LCs into the epidermis (Wong
and Buck, 1971).
An entirely new line of thinking about the derivation of LCs
emerged when the unique cytoplasmic organelles of these
cells, i.e., the pentalaminar Birbeck granule, were detected
within histiocytes of lung and bone lesions of patients suffering
from what was called at that time ‘‘histiocytosis X’’ (Basset
et al., 1966). Subsequently, it became clear that these
neoplastic cells exhibit essentially all of the phenotypic
features of LCs (Nezelof et al., 1973), and it was only logical
to rename the disease ‘‘LC histiocytosis’’. One hundred years
after Langerhans seminal discovery, the concept of a histo-
genetically heterogeneous epidermis prevailed, consisting of
epithelial keratinocytes, neuroectodermal melanocytes, and
mesenchymal LCs (Wolff, 1972). Why ‘‘mesenchymal’’? This
is not entirely clear, but, in the late 1960s, histiocytes were
probably considered to be of mesenchymal origin.
LANGERHANS CELLS AS IMMUNOCYTES—THE EARLY
YEARS
After the mid-1970s, a series of observations led to a radical
change in our understanding of LC biology. These cells were
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then recognized as bone marrow–derived leukocytes (Katz
et al., 1979; Volc-Platzer et al., 1984) with an immunophe-
notype similar to antigen-presenting monocyte–macrophages
and dendritic cells, respectively (Stingl et al., 1980). At the
functional level, it was demonstrated convincingly that
epidermal cells enriched for LCs, but not those depleted of
LCs, were potent stimulators of antigen (haptens, soluble
proteins, alloantigens)-specific T-cell proliferation in an
major histocompatibility complex II-dependent manner
(Stingl et al., 1978; Braathen and Thorsby, 1980). These
in vitro findings were complemented by in vivo data that also
implied an immunological role for these cells. In contact
eczema, Silberberg et al. (1976) found a close apposition of
LCs and lymphocytes and, subsequently, reduction and
damage of LCs. The Dallas group, on the other hand,
provided evidence for a direct relationship between epider-
mal LC density and the successful induction of contact
hypersensitivity (Toews et al., 1980) and allograft immunity
(Streilein et al., 1982). Particularly important was the
observation that the attempted hapten sensitization via
LC-depleted skin was not an immunological null event,
but rather resulted in antigen-specific unresponsiveness.
The sensitizing power of LCs was also underscored by the
stunning observation that LCs induced contact hypersensitiv-
ity even under experimental conditions that normally would
result in tolerization (Ptak et al., 1980).
Altogether, these data implied that antigenic contact of
LCs would invariably result in a productive immune
response. This idea was maintained for quite some time,
although its consequences, i.e., constant tissue inflam-
mation as a result of immunity to self and non-self, would
not be compatible with skin homeostasis and integrity. In the
mid-1980s, evidence was presented indicating that the
immunostimulatory capacity of LCs depends on the quality
and quantity of external signals and stimuli. Schuler and
Steinman (1985) reported that freshly isolated LCs appear as
round cells, express only modest amounts of major histo-
compatibility complex antigens and costimulatory molecules
on their surfaces, and are only poor stimulators of primary
immune responses. After several days of coculture with their
epidermal symbionts, however, they had assumed a highly
dendritic configuration, expressed high amounts of major
histocompatibility complex and costimulatory molecules,
and evoked vigorous responses in naive resting T cells. It
soon became clear that the delivery of ‘‘danger’’ signals
(Matzinger, 1994) such as highly reactive haptens leads to a
marked increase in the production and release of proin-
flammatory and immunostimulatory cytokines by keratino-
cytes (Enk and Katz, 1992) and that some of these cytokines,
e.g., GM-CSF and IL-1, are essential for the viability and
immunostimulatory function of cultured murine epidermal
LCs (Witmer-Pack et al., 1987; Heufler et al., 1988).
What did this finding tell us about in vivo circumstances?
A large number, because under stress conditions (e.g., skin
explants), of LCs undergo the same phenotypic changes as do
single epidermal cell cultures in vitro (Larsen et al., 1990).
Together with the finding by Romani et al. (1989) that freshly
isolated LCs present large protein antigens more efficiently to
T-cell clones than do cultured LCs, it was believed that LCs
pick up and process antigenic moieties in situ and, upon
receipt of danger signals only, start to mature phenotypically
and functionally and migrate to the T-cell zones of regional
lymph nodes. Once arrived, they would ultimately come into
prolonged contact with antigen-specific, naive resting T cells,
leading to their activation. This concept also implied that,
under homeostatic, non-dangerous conditions, LCs would be,
at best, exposed to innocuous substances (e.g., self-proteins)
and this encounter would neither entice them to migrate nor
induce immunological maturation.
LANGERHANS CELLS AS IMMUNOCYTES—NEW
DEVELOPMENTS
As described above, by about the end of the last century a
large body of evidence for an immunogenic role of LCs had
accumulated. LCs were considered as being responsible for
inducing essentially all immune responses that originate in
the skin, especially in the epidermis. New developments
in LC research, however, have markedly changed the way
we see LCs. Two concepts have now been challenged:
(1) that LCs are the major antigen-presenting cells in skin and
(2) the fact that LCs are invariably immunogenic needs
reconsideration.
Important accelerators for LC research
Discovery of langerin. The key discovery that set off a
veritable boom in LC research was made by Jenny Valladeau
and Sem Saeland about 12 years ago. They followed up on
early descriptions of an LC-specific molecule, the ‘‘Lag’’
antigen (Kashihara et al., 1986), and found and characterized
a C-type lectin receptor that was specifically expressed in and
on LCs; they therefore named it ‘‘langerin’’ (CD207;
Figure 1. A group of Langerhans cell researchers visiting the grave of
Paul Langerhans in Funchal, Madeira, Portugal in 2005. From left to right:
Georg Stingl, Ralph Steinman, Rick Granstein, Marcel Teunissen (kneeling),
Mark Udey, Lasse Braathen, Mieke Mommaas, Geoffrey Rowden, Kunihiko
Tamaki, and Paul Bergstresser. Someone (Niki Romani) had to take the
photograph. Both Kunihiko Tamaki and Ralph Steinman have died since this
photograph was taken.
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Valladeau et al., 1999, 2000). Langerin is also a major
molecular constituent of Birbeck granules. Excellent anti-
bodies against langerin became available, allowing a direct
and simple identification of LCs outside the familiar environ-
ment of the epidermis.
Genetically modified mice. Progress in genetic engineering
led to the generation of mice that had GFP (green fluorescent
protein) coupled to langerin as a reporter dye for easy and
straightforward identification and sorting of langerin-expres-
sing cells (Figure 2; Kissenpfennig et al., 2005). Equally
important, mice were devised in which langerin-expressing
cells could be removed selectively by means of diphtheria
toxin (Bennett et al., 2005; Kissenpfennig et al., 2005) or
where LC never even appeared—also based on diphtheria
toxin technology (Kaplan et al., 2005).
Non-LC dendritic cell in skin. Undoubtedly, LCs were the
first skin dendritic cells to be discovered and characterized.
For a long time, they were therefore considered to be the
main, if not the only, dendritic cell of the skin. However, this
turned out to be incorrect.
In the beginning of the 90s, dermal dendritic cells were
discovered (Lenz et al., 1993; Nestle et al., 1993): an
important additional cutaneous dendritic cell had entered the
stage. Since then, much knowledge has been gathered about
these cells, but their true identity is not as crystal clear as that
of classical LCs. In normal healthy epidermis, LCs are the
only type of antigen-presenting cells. This makes definitions
easy. The dermis, in contrast, contains different hematopoi-
etic cells, including closely related ones such as dendritic
cells and macrophages. Their exact ontogenetic relationship
has not been completely clarified, but we now have some
good markers at hand, such as CD163, which allow
separation of dermal dendritic cells from macrophages (Zaba
et al., 2007; Teunissen et al., 2011).
Another degree of complexity was added in 2007, when a
novel type of dendritic cell was detected in the murine dermis
(Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al.,
2007). Until then, the rare langerinþ cells in the steady-state
dermis had been considered LCs that just happened to be in
transit from the epidermis through the dermis toward lymph
nodes. Now we know that they represent, at least partly,
another population of langerinþ dendritic cells in the
dermis. These cells are not radioresistant as their epidermal
counterparts, meaning that in bone marrow transplant
experiments they are readily replaced by donor cells in
contrast to LCs, which remain of recipient origin for virtually
the whole life (Merad et al., 2002; Kanitakis et al., 2011).
Langerinþ dermal dendritic cells are dependent on Flt-3
ligand in their development, in contrast to LC, which develop
independently of Flt-3 ligand but which need CSF-1
(Ginhoux et al., 2012). They also differ phenotypically. The
main markers that set langerinþ dermal dendritic cells apart
from LCs are CD103, which they express, and EpCam/
CD326, which they do not express. CD103þ langerinþ
dermal dendritic cells have so far been characterized only in
the mouse. Although they are very rare in situ and can hardly
be spotted by immunofluorescence or immunohistochemis-
try, they can be readily detected in migrant populations of
skin explants (Flacher et al., 2010; Sparber et al., 2010) or,
even more so, in analyses of skin-draining lymph nodes,
where they make up a substantial proportion (up to 50%) of
all langerinþ cells (Tripp et al., 2009). Langerinþ /CD103þ
dendritic cells in the dermis seem to be part of a dendritic cell
system that also occurs in other tissues such as lung and gut
(Ginhoux et al., 2009; Helft et al., 2010).
Langerhans cells are not (always?) immunogenic
Two important insights were gained in the past 10 years with
regard to dendritic cell function in general and LC function in
particular, leading us no longer to state categorically that
‘‘Langerhans cells are immunogenic.’’
Dendritic cells can function in a tolerogenic way: a new
paradigm. Traditionally, dendritic cells were regarded as
primarily or solely immunogenic. The late Ralph M. Stein-
man, who received the 2011 Nobel Prize in Medicine, even
named them ‘‘nature’s adjuvant’’ (Steinman et al., 1990).
Around 2002/2003, it became feasible to deliver antigens to
mice in vivo, in the absence of perturbations that, via the
engagement of Toll-like receptor (TLR) or other pattern
recognition receptor, would ordinarily signal danger and,
thus, cause inflammation. For this purpose, model antigens
were coupled to antibodies against C-type lectin receptors
expressed by dendritic cells, typically DEC-205/CD205, and
mice were immunized with these conjugates. This did not
result in a so-called ‘‘null event’’, but rather a state of
tolerance developed after an initial wave of T-cell prolifera-
tion. Only when inflammatory stimuli such as CD40 ligand or
TLR ligands were given along with the antigen did immunity
develop (Hawiger et al., 2001; Bonifaz et al., 2002). These
seminal experiments, which were conducted largely in Ralph
Steinman’s Rockefeller University labs, taught two lessons.
First, immune responses can be markedly enhanced when
antigens are ‘‘targeted’’ to uptake receptors on dendritic cells
and administered together with inflammatory stimuli. This
principle can be harnessed for immunotherapy, e.g., against
cancer (Bonifaz et al., 2004) and for improving vaccination in
general (Romani et al., 2010b; Flynn et al., 2011). Second,
ADPase
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GFP
2011
Figure 2. Epidermal sheets from mouse ear skin. Thirty years ago, Langerhans
cells were visualized by the classical ATPase/ADPase enzyme reaction (left).
At present, Langerhans cells can be observed directly, without any antibodies,
by means of green fluorescent protein (GFP) expressed along with langerin
(right; black/white mode). Although the cells still look alike, our views on
their biology have changed considerably (GFP photo by Florian Sparber).
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and more relevant in the context of our discussion, antigens
given in the absence of danger signals induce tolerance
(Steinman et al., 2003). This is the proposed mechanism for
inducing and maintaining peripheral tolerance to self-
antigens (Steinman and Nussenzweig, 2002) and to innoc-
uous substances. This concept of tolerance brought about by
dendritic cells in the steady state was based on experiments
that did not specifically address the role of LCs in this process.
Implicitly, of course, LCs and other skin dendritic cells must
have been involved because the preferred route of immuni-
zation was the skin (mostly mouse footpad).Nevertheless, no
special attention was payed to these subsets of dendritic cells.
Langerhans cells do not induce productive/protective
immunity: a provocative notion. The first ‘‘blow’’ to the
belief that LCs are universally immunogenic came when
Allan et al. showed in 2003 that in a mouse model of
cutaneous herpes virus infection it was not LCs that would
present the viral antigen to CD8þ T cells in the lymph node,
but rather lymph node–resident dendritic cells (Allan et al.,
2003). The failure of LCs to present in this model could, in
part, be explained by their likely destruction in the skin by the
cytopathic virus (Bosnjak et al., 2005). As a consequence,
lymph node–resident dendritic cells would step in. Indeed, in
other mouse models, where cytopathic and non-cytopathic
viruses were compared, skin-derived dendritic cells did
transport and present the virus to T cells (He et al., 2006).
LCs and other dendritic cell subsets of the skin were not
distinguished in this study. Similar observations were made in
the murine vagina where submucosal dendritic cells, but not
LCs, induced protective T helper type 1 responses to herpes
simplex virus-2 (Zhao et al., 2003). In addition, in a murine
leishmania skin infection model, the parasites were presented
in the draining lymph nodes by dendritic cells other than
LCs (Ritter et al., 2004). The other initial doubts about a
universally immunogenic function of LCs were raised by the
first studies using murine cell–depletion models in contact
hypersensitivity. Mice that were depleted of all langerinþ
cells (diphtheria-toxin receptor model; ‘‘DTR mice’’) showed
unimpaired ear swelling responses (Kissenpfennig et al.,
2005), and mice that had no LCs from birth (diphtheria toxin
expression model; ‘‘DTA mice’’) even developed enhanced
ear swelling responses (Kaplan et al., 2005).
In this context, it is important to emphasize that in this
quickly evolving research field confusion may stem from
the rapid sequence of discoveries. Data from 2006 could not
yet take into account the existence of langerinþ dermal
dendritic cells that were only published in 2007. This
potential problem is often overlooked.
Using the mentioned models, a substantial number of
studies have been published over the past few years. The
more recent among them did in fact take into account
langerinþ dermal dendritic cells as critical factors in cuta-
neous immune responses. Evidence accumulates that, at least
in mice, LCs appear to fulfill primarily a downmodulatory
role, and that it is mainly langerinþ dermal dendritic cells
that subserve immunogenic functions. An immune-dampen-
ing function of LCs in vivo was recently shown in a mouse
model of cutaneous Leishmania infection (Kautz-Neu et al.,
2011), as well as in skin-grafting experiments (Obhrai et al.,
2008). A likely underlying mechanism in this setting is the
expansion of regulatory T cells induced by LCs (Kautz-Neu
et al., 2011). This capacity of LCs was already noted some
time ago, and it was shown to depend on receptor activator of
NF-kB ligand produced by neighboring keratinocytes (Loser
et al., 2006). This may also account for the observed
T-regulatory induction by LCs (but not by langerinþ dermal
dendritic cells) in the setting of UVB-induced immune
suppression (Schwarz et al., 2010). These findings in mouse
models were recently corroborated in clinical human samples
and with human LCs. Glucocorticoids influenced LCs in such a
way that they would induce regulatory T cells in a transforming
growth factor-b-dependent manner (Stary et al., 2011). If LCs
were to use their T-regulatory-inducing capacity to subserve a
tolergenic function in the steady state, i.e., non-inflamed skin,
they need to be able to take up and cross-present self-antigens
within the intact epidermis as a precondition. Indeed, this was
shown unequivocally in a mouse in which the antigen could
be inducibly expressed in keratinocytes: LCs isolated from this
epidermis readily activated antigen-specific T cells, indicating
that they must have captured and processed the antigen in
the steady state (Holcmann et al., 2009). Langerinþ dermal
dendritic cells were absent in this experimental system
(trypsinized epidermis).
Conversely, evidence increases for an immunogenic role
of langerinþ dermal dendritic cells. The Melbourne group
delved into the mouse herpes virus infection model in more
detail. In particular, they studied the phase of viral recruden-
scence where cytopathic effects of virus are much less
pronounced than in primary infection (Bedoui et al., 2009).
There, as well as in accompanying experiments with an
epidermis-restricted (i.e., expressed under a keratin promoter)
antigen, it was clearly the population of CD103þ /CD8-
negative/CD205þ dendritic cells that cross-presented the
antigens in the skin-draining lymph nodes. Similar observa-
tions were made by the group of Henri et al. (2010). In both
studies, LCs contributed only little, if anything, to cross-
presentation. This contrasts with LCs freshly isolated from the
epidermis, which do cross-present the epidermis-restricted
antigen (Stoitzner et al., 2006; Holcmann et al., 2009). The
reasons for these differences remain to be determined. Thus,
CD103þ /langerinþ dermal dendritic cells behave function-
ally similar to their CD103þ (but only partly langerinþ )
counterparts in other tissues of the mouse. They appear to be
the major cross-presenters in the skin (Chang and Kweon,
2010; del Rio et al., 2010; Helft et al., 2010). It will be
interesting to see how relevant these data from mouse models
will be for the human situation. Human counterparts for the
langerinþ dermal dendritic cell have not yet been described,
but they may be defined and characterized soon (Teunissen
et al., 2011).
Thus, LCs may not be operative in cross-presenting viral
or tumor antigens in vivo. Nevertheless, they are not inactive!
They are able to present antigens to CD4þ T cells in vivo, as
demonstrated in the herpes infection model (Bedoui et al.,
2009). This would allow them to induce regulatory T cells as
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discussed above. Underscoring this, LCs can induce contact
hypersensitivity all by themselves, i.e., under experimental
conditions where the hapten does not reach the dermal
dendritic cells (Noordegraaf et al., 2010) or when langerinþ
dermal dendritic cells are not present (Honda et al., 2010). The
capacity of LCs to process and present to CD4þ T cells in vivo
explains the recent observations that the production of IgG1
antibodies in response to gene gun immunization is dependent
on LCs as suggested in one study (Nagao et al., 2009). Another
study reminds us that the last word has not been spoken yet
over this issue (Stoecklinger et al., 2011). Finally, LCs but not
langerinþ dermal dendritic cells turn out to be responsible for
the activation of T helper type 17 T cells in response to a fungal
infection of the skin (Igyarto et al., 2011). As we will discuss
below, there may even be conditions under which LCs can also
cross-present and induce major histocompatibility complex
I-restricted cytotoxicity to be possibly used for the immuno-
therapy of cancer.
UNRESOLVED QUESTIONS—THE FUTURE OF THE
LANGERHANS CELL
In spite of the tremendous progress in the field, we are far
from completely understanding the biology of LCs. Unre-
solved questions remain and unexpected new functional
features have emerged. Here we present and briefly discuss a
number of such issues.
LCs in innate immunity
It has been known for a long time that LCs can be infected
by HIV-1 (Tschachler et al., 1987). In fact, they have been
regarded as being pivotal in disseminating the virus to
proliferating CD4þ memory T cells (Pope et al., 1994;
Sugaya et al., 2004). This role of LCs in the promotion of
HIV-1 infection was recently challenged by the finding that
LCs can bind to the virus via langerin and degrade it in their
Birbeck granules, thus preventing viral transmission to T cells
(de Witte et al., 2007). This may be the first example of an
innate defense mechanism exhibited by LCs. Measles virus
may be treated similarly by LCs (van der Vlist et al., 2011).
Other effector functions of LCs worth investigating include
the synthesis of complement components, the secretion of
antimicrobial peptides, and arachidonic acid metabolites. For
the latter class of substances, LCs were, indeed, shown to be
important producers of prostanoid synthases, and thus
responsible for flushing in response to nicotinic acid drugs
(Benyo et al., 2006). Imiquimod treatment of basal cell
carcinoma of the skin leads to regression and clearance of
this tumor. This is mediated by dendritic cells rather than—as
would have been expected—by cytotoxic T cells (Stary et al.,
2007). These dendritic cells possessed molecules of the lytic
machinery, and it would be interesting to explore how LCs
behave in this regard. Can they also be induced to make, for
instance, perforin and granzyme? Can LCs develop the
machinery for intracytoplasmic killing of microorganisms
and immune phagocytosis? On the basis of the lack or low
expression of TLRs recognizing bacterial molecules (TLRs 2
and 4), Teunissen hypothesizes that LCs may not be the prime
defenders against bacteria but, rather, may contribute to
tolerance against commensal bacteria (van der Aar et al.,
2007). Clearly, this problem still needs considerable research.
Langerhans cells in adaptive immunity
From all that has been said so far, it is clear that LCs are
prototypic antigen-presenting cells. Unfortunately, the quality
of the immune response induced under different in vivo
conditions is far from certain. This is particularly true as far as
their role in anti-microbial immunity is concerned. Protection
against HSV-2 might be mediated by vaginal submucosal
dendritic cells but not LCs (Zhao et al., 2003), and LCs might
even be counterproductive in mounting a protective immune
response by dampening genital cytotoxic responses following
mucosal immunization (Hervouet et al., 2010). Although
certain studies with mice, whose langerin-positive cells had
been eliminated by genetic manipulation (Kaplan et al.,
2005), indicate that LCs, at least under homeostatic condi-
tions, induce antigen-specific unresponsiveness, it is not yet
clear whether this is also true when an overwhelming danger
signal (e.g., virulent microorganisms) occurs in skin. It is quite
likely that such an event would induce maturational steps in
LCs and allow these cells to join forces with other dendritic
cells in the process of T-cell sensitization. Altogether, it is
quite likely that the actual function of an LC in situ is
determined by stimuli from the environment and/or their
epidermal symbionts. In unperturbed skin or under the
influence of hormone drugs (e.g., glucocorticosteroids; Stary
et al., 2011), they are most likely concerned with down-
regulating T-cell responses.
In other situations, the immunological outcome may be
quite different. LCs can stimulate type 2 T-cell responses
(Hauser et al., 1989) and do it in a particularly efficient
manner under the influence of thymic stromal lymphopoietic
(Ebner et al., 2007). This pathway appears to be operative in
atopic dermatitis. The role, if any, of LCs in the activation of
Th-17 cells is less clear and, even, controversial (Aliahmadi
et al., 2009; Duraisingham et al., 2009; Mathers et al., 2009;
Wang et al., 2011).
Interestingly, human LCs have been reported to induce
distinct CD4þ T cells that produce IL-22, but not IL-17
(Fujita et al., 2009). The relevance of these findings for our
understanding of the immunopathogenesis of diseases such
as atopic dermatitis or psoriasis is not yet clear. There are
reports that the number of LCs is reduced within lesional
psoriatic skin (Ashworth and Mackie, 1986; Bieber et al.,
1988; Placek et al., 1988; Jones et al., 1994), although the
extent is largely dependent on the mode of quantification.
The reduction observed can be reverted by the tumor necrosis
factor-a-antagonist adalimumab (Gordon et al., 2005). It was
shown that this decrease in LC count distinguishes psoriasis
from other chronic inflammatory skin diseases such as lichen
planus and inflamed seborrheic keratosis (Gordon et al.,
2005), which underlines a possible local anti-inflammatory
role of these cells. Consistently, it has been shown previously
that tumor necrosis factor-a leads to the exodus of LCs from
both murine and human epidermis (Cumberbatch et al.,
1994, 1999, 2003; Kimber et al., 2000). In any event, we
urgently need molecular biological, as well as functional,
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studies with cells directly isolated from the affected tissues to
address these questions appropriately.
A most important, yet unresolved, question is whether LCs
can be induced to evoke type 1 T-cell responses (Rajkovic
et al., 2011) and thus, at least theoretically, be used as
vehicles in trans- or epicutaneous approaches for vaccination
against microbial and tumor antigens. Such desirable
‘‘needle-free’’ approaches are already being commercialized
for vaccination, so far with varying degree of success (Glenn
et al., 2007). Antitumor effects in mice could be achieved by
epicutaneous immunization with tumor antigen (Stoitzner
et al., 2008). Whether they were mediated by LCs alone or
together with with langerinþ dermal dendritic cells was not
assessed. It is, therefore, not certain how beneficial it would
be to address LCs as the primary target in an epicutaneous
approach. The open question is still the ability of LCs to cross-
present. The mouse models discussed above suggest strongly
that langerinþ dermal dendritic cells, rather than LCs, cross-
present. This notion is supported by recent work from
Geijtenbeek’s group (van der Vlist et al., 2011), who infected
human LCs, isolated from the epidermis, with measles virus.
Although LCs were able to present virus epitopes to CD4þ
T cells, they were unable to cross-present it to CD8þ T cells.
In vitro generated ‘‘LCs’’, in contrast, could readily and
efficiently cross-present (Ratzinger et al., 2004; Klechevsky
et al., 2008). Only when the antigen was targeted to an
antigen uptake receptor on LCs (human DCIR in that case)
by means of an antibody conjugated to the antigen could
CD8þ T-cell responses be measured by pentamer staining
and IFN-g release, thus indicating true cross-presentation
(Klechevsky et al., 2010). This validates data by Stoitzner
et al. (2006) who have demonstrated unequivocally that
murine LCs can cross-present; contamination by langerinþ
dermal dendritic cells could be definitively excluded in these
experiments.
A critical variable that may determine whether LCs can be
successfully harnessed to improve vaccination (Ueno et al.,
2010) may be the manner of targeting these cells. Several
surface receptors are candidates (DEC-205/CD205, langerin,
DCIR, Clec9A, and so on), and it is not yet known how
targeting one or the other receptor on LCs will shape the
ensuing immune responses. The fact that there are important
differences has already been shown for dendritic cells other
than LCs (Dudziak et al., 2007; Idoyaga et al., 2008). Future
research will have to identify methods of targeting and
activating LCs that lead to the most efficient (cross-)presenta-
tion of vaccine antigens applied to the skin, and thus protect
from pathogens and control, or even cure, cancer.
Role of LCs in the maintenance of epidermal biology
LCs are prone to primarily populate stratified squamous
epithelia. The reason for this affinity is only poorly under-
stood, and the interaction between MIP-3a (CCL20) and
CCR6 may be only one factor involved. Having arrived in
the epidermis, LCs preferentially occupy a suprabasal
position. We know that anchoring of LCs to the surround-
ing keratinocytes is, at least partly, mediated by E cadherin–
dependent homotypic adhesion, but other attachment
1868 1961 1980
1985
Regional lymph node Langerhans cell Dermal dendritic cell
2005 20XX
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Figure 3. Roles attributed to LCs during the past 143 years. (a) Langerhans cells (LCs) as sensory nerve endings; (b) LCs as ‘‘effete’’ melanocytes; (c) LCs
exclusively mediating a productive immune response. (d) Only activated LCs mediate a productive immune response, whereas unperturbed LCs remain inactive;
(e) LCs dampen immune responses; (f) LCs as mediators of multiple functions, depending on environmental factors.
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molecules such as claudin probably do also have a role
(Zimmerli and Hauser, 2007). These bonds between LCs and
keratinocytes must also be dynamic. One has to imagine that
LCs localize in the epidermis for years (Merad et al., 2002;
Kanitakis et al., 2011), whereas keratinocytes constantly
differentiate around them and move up in the epithelial tissue
until they ultimately desquamate. The movement of LCs is
also a prerequisite for their antigen-capturing capacity. For
this purpose, LCs reach out with their dendrites, penetrate
through tight junctions, and pick up antigens or pathogens
that have successfully passed the stratum corneum barrier but
cannot get further because of the tight junctions (Kubo et al.,
2009). The intraepidermal movement of LCs has been
beautifully visualized (Kissenpfennig et al., 2005; Vishwanath
et al., 2006), but the molecular events governing this process
are only poorly understood. In any case, we can safely
assume that the intraepidermal LC population is a ‘‘stably
moving’’ network, always alert and ready to react to external
stimuli. The fact that LCs and their epidermal symbionts form
a functional unit does not necessarily mean that LCs have a
role in epidermal homeostasis. LC-free epidermis in DTR
knock-in mice did not show overt alterations (Kissenpfennig
et al., 2005), and there were no abnormalities in epidermal
structure reported in mice that do not possess epidermal LCs
from birth (‘‘DTA mice’’; Kaplan et al., 2005). As epidermal
differentiation was not a major issue in these studies, it
may well be that more thorough and directed studies of
several parameters of keratinocyte differentiation may reveal
an influence of LCs. Such an influence was, indeed,
suspected many years ago by Potten and Allen (1976),
who concluded it from the conspicuous array of keratinocytes
and LCs in the epidermis (‘‘epidermal proliferative unit’’).
We have already mentioned that LCs can induce T cells
to produce IL-22, the main ‘‘fuel’’ for the proliferation of
keratinocytes. LCs can therefore influence epidermal homeo-
stasis indirectly via helper T cells. Whether they can do it
directly, i.e., without mediation by helper T cells, remains to
be determined.
Role of Birbeck granules
For many years we liked to call these organelles ‘‘enigmatic’’.
They have lost much of their enigmatic character recently.
We now know that they are composed of langerin (and
certainly other molecules as well). We know that they are
part of the endosomal recycling pathway (Mc Dermott et al.,
2002; Uzan-Gafsou et al., 2007). Do they fulfill other
specialized tasks in addition to serving as ‘‘virus-cracking’’
organelles, as suggested (de Witte et al., 2007)? Interestingly
enough, the one and only healthy individual identified to
date (by serendipity), who lacks Birbeck granules because of
a mutation in the langerin gene, showed no obvious
manifestations of this defect (Mommaas et al., 1994; Verdijk
et al., 2005). Similarly, pig skin, whose LCs do not contain
Birbeck granules (Bautista et al., 2002), has no conspicuous
phenotype.
There are many other interesting aspects of LC biology
(e.g., contribution of LC to the immunogenicity of skin grafts;
role of LC in skin aging; LCs as drug targets and so on), but
their detailed description would exceed the scope of this
article.
Two of the authors of this manuscript have lived through
exciting early (NR) and very early (GS) stages of LC research
and have contributed seminal evidence for an immunogenic
role of LCs. Therefore, it is ‘‘emotionally’’ somewhat difficult
for us to accept a thoroughly different, even opposing, view
about the function of our ‘‘favorite’’ cells (Figure 3).
Scientifically, however, we are thrilled and fascinated by
the progress that we observe and that we are privileged to be
part of. It is reassuring and ‘‘consoling’’ to learn that LCs
remain to be a very important and crucial cell in the immune
system of the skin, in spite of changing paradigms. Unless
research funding decreases markedly, for which we do not
hope, LC research has a bright future.
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